Stock Commentary - New York
9 May 2005
Stock Commentary - New York
28 April 2005
Herceptin to become a blockbuster drug?
27 April 2005
APP reports start of Ph II trial of Abraxane/Herceptin
18 April 2005
PacMab raises fund for new cancer therapy
21 March 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
Roche disappoints despite 116% net income hike
7 February 2005
Taxotere cleared for two new indications
17 January 2005
Roche's Genentech gamble pays off
13 December 2004
UK industry figure slams lack of drug access
8 November 2004
Japan's Chugai posts nine-month results in line with forecasts
8 November 2004
Genentech and Wyeth in manufacturing accord
4 October 2004
Innovative drugs and their impact on the future of oncology developments
20 September 2004
Genentech's 2nd-qtr sales rocket 42%
19 July 2004
Stock Commentary - Europe
28 June 2004
Roche expands biotech production capacity
28 June 2004
New use in EU for Roche's Herceptin
28 June 2004
Stock Commentary - New York
14 June 2004
Letter from the Editor
31 May 2004
Genentech's sales up 28% for 1st-qtr 2004
19 April 2004
Roche beats forecasts with sales up 19%
9 February 2004
Applied Imaging gets FDA nod for breast cancer test
26 January 2004
Herceptin offers no benefit in lung cancer
30 November 2003
UK "post-code Rxing" of Roche's Herceptin
27 October 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Stock Commentary - New York
20 October 2003
Herceptin combi helps breast cancer survival
6 October 2003
Tokyo pharma stocks - week to July 28
4 August 2003
Roche posts sharp fall in 1st-half profit
28 July 2003
Genentech swings to profit as sales soar
14 July 2003
Strong growth for Genentech in 1st-qtr
21 April 2003
Genentech
20 January 2003
Genentech posts $214M loss in 2nd qtr
22 July 2002
GSK says no to cancer deal with Immunogen
1 July 2002
Herceptin disappoints in lung cancer
3 June 2002
Genentech 1st-qtr earnings leap
22 April 2002
UK NICE's proposed guidance timetable
25 March 2002
UK's NICE gives backing to Roche's Herceptin
25 March 2002
Tokyo pharma stocks - week to February 18
25 February 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
AstrAZeneca files Iressa for NSCLC in Japan
4 February 2002
Fujisawa approval to import Vysis to Japan
28 January 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
Test backed to screen patients for Herceptin
6 December 2001
Genentech boosted by Avastin study
26 October 2001
Genentech third-qtr revenues jump 24%
16 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
Antisoma: strong fundamentals belie near-term financing troubles
10 October 2001
Oncologist slams Australian PBAC
28 September 2001
Genentech earnings set to grow 25%
11 September 2001
Net income increases 28% at Genentech
12 July 2001
Genentech wins dispute on cancer drug patents
10 May 2001
Stock Commentary - New York
19 April 2001
Dip in 1st-qtr pharma sales at Roche
11 April 2001
Roche gets approval in Japan for Herceptin
5 April 2001
Stock Commentary - Europe
22 March 2001
Published Herceptin data lift Genentech
16 March 2001
Stock Commentary - New York
8 March 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Genentech net income rises 30% for 2000
23 January 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
Synergy seen with Aptosyn and Herceptin, Taxotere
13 December 2000
Aventis and Roche in global cancer R&D link
7 December 2000
GW wins over Roche in oncology drug lawsuit
2 November 2000
Genentech's Herceptin has survival benefit
19 October 2000
Genentech sees 25% increase in product sales
12 October 2000
Roche's Herceptin introduced onto Euro market
28 September 2000
B-MS buying back $2 billion in shares
22 September 2000
Roche gains EC clearance to market Herceptin
31 August 2000
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
